351. Antiproliferative and Antiangiogenic Effects of Zerumbone from Zingiber zerumbet L. Smith in Sprague Dawley Rat Model of Hepatocellular Carcinoma.
- Author
-
Samad, Nozlena Abdul, Abdul, Ahmad Bustamam, Rahman, Heshu Sulaiman, Abdullah, Rasedee, Ibrahim, Tengku Azmi Tengku, and Othman, Hemn Hassan
- Subjects
- *
SPRAGUE Dawley rats , *HEPATOCELLULAR carcinoma , *ENDOSTATIN , *VASCULAR endothelial growth factors , *ONE-way analysis of variance , *ZINGIBER - Abstract
Context: Zerumbone (ZER) is known to exhibit anticancer properties on various cancer cells both in vitro and in vivo. However, the anti-angiogenesis effect of ZER on liver cancers in vivo is not yet addressed clearly. Aims: This study aimed to investigate the in vivo antiproliferative and antiangiogenesis effects of ZER using rats with diethylnitrosamine-induced hepatocellular carcinoma (HCC). Materials and Methods: The antiproliferative and anti-angiogenesis effects of ZER were determined using the hepatosomatic index, vascular endothelial growth factor (VEGF) immunoassay, terminal deoxynucleotidyl transferase dUTP nick end labeling assay, histopathology, and immunohistochemistry analysis. Results: Nontreated rats with HCC had higher median liver weight than those treated with ZER or suramin. The expression of VEGF, matrix metalloprotease, and Ki-67 that were high in nontreated HCC rats was down-regulated with ZER or suramin treatments. Statistical Analysis Used: Statistical analyses were performed using the Statistical Package for Social Science version 21.0 (SPSS Inc, IBM, Maryland, USA). The data were expressed as the mean ± standard deviation and analyzed using a one-way analysis of variance. P < 0.05 was considered statistically significant. Conclusion: ZER has the potential to be developed as the pro-apoptotic and antiangiogenic agent in the treatment of HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF